Dovepress 76. Yung A, Reay N, Goodfield MD. Improvement in digital flexibility and dexterity following ingestion of sildenafil citrate (Viagra) in limited systemic sclerosis. Arch Dermatol. 2005;141:831–833. 77. Sandorfi N, Jimenez SA. Treatment of digital ulceration due to Raynaud’s phenomenon (RP) with long acting phosphodiesterase 5 (PDE5) inhibitor: tadalafil [abstract]. Ann Rheum Dis. 2007;66(Suppl 2): 223–224. 78. Friedrichson E, Rehberger P, Fuhrmann JT, Walz F, Meurer M, Pfeiffer C. Fast and efficient healing of scleroderma-associated acral ulcers with sildenafil. Hautarzt. 2008;59:230–232. 79. Lal A, Fernando CE. Efficacy of vardenafil in a patient with digital gangrene due to severe Raynaud’s [abstract]. ACR/ARHP Scientific Meeting 2007. Boston, MA: November 6–11, 2007; Abstract CRC04. 80. Della Rossa A, Doveri M, D’Ascanio A, et al. Oral sildenafil in skin ulcers secondary to systemic sclerosis [abstract]. Ann Rheum Dis. 2009; 68(Suppl 3):268. 81. Friedman EA, Harris PA, Wood AJJ, Stein CM, Kurnik D. The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud’s phenomenon. Clin Pharmacol Ther. 2007;81:503–509. 82. Bolte MA, Avery D. Case of fluoxetine-induced remission of Raynaud’s phenomenon – a case report. Angiology. 1993;44:161–163. 83. Rey J, Cretel E, Jean R, Pastor MJ, Durand JM. Serotonin reuptake inhibitors, Raynaud’s phenomenon and erythromelalgia. Rheumatology. 2003;42:601–602. 84. Buecking A, Rougemont E, Zullino DF. Treatment of Raynaud’s phenomenon with escitalopram. Int J Neuropsychopharmacol. 2005; 8:307–308. 85. Coleiro B, Marshall SE. Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology. 2001;40:1038–1043. 86. Bell C, Coupland N, Creamer P. Digital infarction in a patient with Raynaud’s phenomenon associated with treatment with a specific serotonin reuptake inhibitor. A case report. Angiology. 1996;47: 901–903. 87. Peiró AM, Margarit C, Torra M. Citalopram-induced Raynaud’s phe- nomenon. Rheumatol Int. 2007;27:599–601. 88. Bertoli R, Girardin F, Russmann S, Lauterburg BH. Raynaud’s phe- nomenon induced by drugs acting on neurotransmission: two cases under reboxetine and one under tegaserod. Eur J Clin Pharmacol. 2003;58:717. Treatment of Raynaud’s phenomenon 89. Rudnick A, Modai I, Zelikovski A. Fluoxetine-induced Raynaud’s phenomenon. Biol Psychiatry. 1997;41:1218–1221. 90. De Broucker T, Lhote F. Severe Raynaud’s phenomenon associated with interferon-beta 1a and fluoxetine. Ann Med Interne (Paris). 2000;151:424–425. 91. Kato S, Kishiro I, Machida M, Fuse D, Yoshida T, Kaneko N. Suppressive effect of sarpogrelate hydrochloride on respiratory failure and right ventricular failure with pulmonary hypertension in patients with systemic sclerosis. J Int Med Res. 2000;28:258–268. 92. Kumagai S, Morinobu A, Ozaki S, Nakao K, Ishida H. Sarpogelate hydrochloride for Raynaud’s phenomenon of patients with collagen diseases. Ryumachi. 1998;38:504–510. 93. Ogawa T, Ogura T, IzumiY, et al. Sarpogelate hydrochloride therapy for Raynaud’s phenomenon in patients with systemic sclerosis [abstract]. Arthritis Rheum. 2008;58(9 Suppl):s821–s822. 94. Sambo P, Amico D, Giacomelli R, et al. Intravenous N-acetylcysteine for treatment of Raynaud’s phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol. 2001;28:2257–2262. 95. Salsano F, Letizia C, Proietti M, et al. Significant changes of peripheral perfusion and plasma adrenomedullin levels in N-acetylcysteine long term treatment of patients with sclerodermic Raynaud’s phenomenon. Int J Immunopathol Pharmacol. 2005;18:761–770. 96. Abou-Raya A, Abou-Raya S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud’s phenomenon and digital ulcers. J Rheumatol. 2008;35:1801–1808. 97. Sycha T, Graninger M, Auff E, Schnider P. Botulinum toxin in the treatment of Raynaud’s phenomenon: a pilot study. Eur J Clin Invest. 2004;34:312–313. 98. Van Beek AL, Lim PK, Gear AJL, Prizker MR. Management of vasospastic disorders with botulinum toxin A. Plast Reconstr Surg. 2007;119:217–226. 99. Fregene A, Ditmars D, Siddiqui A. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud’s phenomenon. J Hand Surg. 2009;34A:446–452. 100. Kossintseva I, Barankin B. Improvement in both Raynaud disease and hyperhidrosis in response to botulinum toxin type A treatment. J Cutaneous Med Surg. 2008;12:189–193. Vascular Health and Risk Management Publish your work in this journal Vascular Health and Risk Management is an international, peer- reviewed journal of therapeutics and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention and treatment of vascular disease and its sequelae; and the involvement of Submit your manuscript here: http://www.dovepress.com/vascular-health-and-risk-management-journal Dovepress metabolic disorders, particularly diabetes. This journal is indexed on PubMed Central and MedLine. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors. Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com Dovepress 177